Browsing: Alzheimer’s drugs

A group of advisers to the Food and Drug Administration (FDA) will convene in the next month to discuss Eli Lilly's new Alzheimer's drug, the company announced on Tuesday. The meeting will take place on June 10, three months after the FDA expressed its intention for experts to carefully assess the safety and effectiveness of the drug, known as donanemab. …

Eli Lilly revealed that the FDA is postponing the approval of its new Alzheimer’s medication and insisting that the company present its safety and effectiveness data to an advisory panel for review. Lilly stated on Friday, "The FDA has told us it needs more insight into evaluating the…"